206 related articles for article (PubMed ID: 31753108)
1. Role of Heredity in Melanoma Susceptibility: A Primer for the Practicing Surgeon.
Abdo JF; Sharma A; Sharma R
Surg Clin North Am; 2020 Feb; 100(1):13-28. PubMed ID: 31753108
[TBL] [Abstract][Full Text] [Related]
2. [From gene to disease; from p16 to melanoma].
Gruis NA; Bergman W
Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
[TBL] [Abstract][Full Text] [Related]
3. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
4. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
Bruno W; Pastorino L; Ghiorzo P; Andreotti V; Martinuzzi C; Menin C; Elefanti L; Stagni C; Vecchiato A; Rodolfo M; Maurichi A; Manoukian S; De Giorgi V; Savarese I; Gensini F; Borgognoni L; Testori A; Spadola G; Mandalà M; Imberti G; Savoia P; Astrua C; Ronco AM; Farnetti A; Tibiletti MG; Lombardo M; Palmieri G; Ayala F; Ascierto P; Ghigliotti G; Muggianu M; Spagnolo F; Picasso V; Tanda ET; Queirolo P; Bianchi-Scarrà G
J Am Acad Dermatol; 2016 Feb; 74(2):325-32. PubMed ID: 26775776
[TBL] [Abstract][Full Text] [Related]
5. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
[TBL] [Abstract][Full Text] [Related]
6. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
7. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S
J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638
[TBL] [Abstract][Full Text] [Related]
8. Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway.
Levin T; Mæhle L
Fam Cancer; 2017 Apr; 16(2):257-265. PubMed ID: 27804060
[TBL] [Abstract][Full Text] [Related]
9. Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers.
Gironi LC; Colombo E; Pasini B; Giorgione R; Farinelli P; Zottarelli F; Esposto E; Zavattaro E; Allara E; Ogliara P; Betti M; Dianzani I; Savoia P
Arch Dermatol Res; 2018 Dec; 310(10):769-784. PubMed ID: 30218143
[TBL] [Abstract][Full Text] [Related]
10. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.
Eskandarpour M; Hashemi J; Kanter L; Ringborg U; Platz A; Hansson J
J Natl Cancer Inst; 2003 Jun; 95(11):790-8. PubMed ID: 12783933
[TBL] [Abstract][Full Text] [Related]
11. CDKN2A germline mutations in individuals with cutaneous malignant melanoma.
Orlow I; Begg CB; Cotignola J; Roy P; Hummer AJ; Clas BA; Mujumdar U; Canchola R; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Wilcox H; Busam K; From L; Berwick M;
J Invest Dermatol; 2007 May; 127(5):1234-43. PubMed ID: 17218939
[TBL] [Abstract][Full Text] [Related]
12. Clinical germline genetic testing for melanoma.
Hansen CB; Wadge LM; Lowstuter K; Boucher K; Leachman SA
Lancet Oncol; 2004 May; 5(5):314-9. PubMed ID: 15120668
[TBL] [Abstract][Full Text] [Related]
13. CDKN2A mutations in multiple primary melanomas.
Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ
N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
Lynch HT; Brand RE; Hogg D; Deters CA; Fusaro RM; Lynch JF; Liu L; Knezetic J; Lassam NJ; Goggins M; Kern S
Cancer; 2002 Jan; 94(1):84-96. PubMed ID: 11815963
[TBL] [Abstract][Full Text] [Related]
15. Familial cutaneous melanoma.
Hansson J
Adv Exp Med Biol; 2010; 685():134-45. PubMed ID: 20687502
[TBL] [Abstract][Full Text] [Related]
16.
Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
Acta Oncol; 2021 Jul; 60(7):888-896. PubMed ID: 33945383
[No Abstract] [Full Text] [Related]
17. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma.
Pho L; Grossman D; Leachman SA
Curr Opin Oncol; 2006 Mar; 18(2):173-9. PubMed ID: 16462187
[TBL] [Abstract][Full Text] [Related]
18. Genetic test reporting enhances understanding of risk information and acceptance of prevention recommendations compared to family history-based counseling alone.
Taber JM; Aspinwall LG; Stump TK; Kohlmann W; Champine M; Leachman SA
J Behav Med; 2015 Oct; 38(5):740-53. PubMed ID: 26178773
[TBL] [Abstract][Full Text] [Related]
19. Pediatric melanoma in melanoma-prone families.
Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA
Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
Dalmasso B; Pastorino L; Ciccarese G; Andreotti V; Grillo F; Mastracci L; Spagnolo F; Ballestrero A; Queirolo P; Bruno W; Ghiorzo P
J Am Acad Dermatol; 2019 May; 80(5):1263-1271. PubMed ID: 30274933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
